Non-Alcoholic Fatty Liver Disease (NAFLD) is a significant global health concern, affecting approximately 25% of the world's population. Characterised by the accumulation of fat in liver cells, NAFLD can progress to more severe conditions like Non-Alcoholic Steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Understanding and managing this disease is crucial to prevent its progression and associated complications.
NAFLD is a multifactorial disease, often associated with metabolic syndrome. The pathophysiology involves insulin resistance, oxidative stress, and lipid metabolism dysregulation. Genetic predisposition, dietary habits, and gut microbiota are also significant contributing factors.
Diagnosis of NAFLD often occurs incidentally during routine blood tests or imaging studies. Elevated liver enzymes, particularly alanine aminotransferase (ALT), can hint towards NAFLD. Ultrasound is the most commonly used imaging modality, but it has limitations in detecting mild steatosis. Liver biopsy, though invasive, remains the gold standard for diagnosing and staging NAFLD.
Management of NAFLD focuses on lifestyle modifications, such as diet changes and increased physical activity, aiming to reduce weight and improve insulin resistance. Pharmacological interventions are considered for patients with NASH or fibrosis. Emerging therapies, including drugs targeting metabolic pathways and fibrosis, are under investigation.
NAFLD's prognosis depends on the stage of the disease and the presence of fibrosis. Regular follow-up with liver function tests and imaging is recommended to monitor disease progression. Patients with advanced NAFLD require surveillance for hepatocellular carcinoma.
In summary, NAFLD is a prevalent disease with potential severe outcomes. Early diagnosis and effective management strategies are vital to prevent disease progression. Ongoing research aims to improve understanding of NAFLD's pathophysiology and develop novel therapeutic interventions.
1.
To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.
2.
Nodal Response After Chemo Helps Tailor Breast Radiotherapy
3.
For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.
4.
In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.
5.
Common intracellular toxin could help fight leukemia
1.
Fibroma: Understanding the Causes, Symptoms, and Treatment Options
2.
Clonal Hematopoiesis and Thrombotic Risk Beyond Cancer: A Comprehensive Review for Clinicians
3.
Unlocking The Causes And Risk Factors Of Breast Cancer
4.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
5.
Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Thromboprophylaxis In Medical Settings
2.
The Role of Hemoglobin in Maintaining Healthy Oxygen Levels
3.
How Multidisciplinary Teams Support Modern Cancer Care
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation